Interestingly, when we focused on ERα positive breast cancer patients that had received tamoxifen as part of their treatment we found that individuals with high ISG12 mRNA expression levels had a significantly worse relapse-free survival rate than patients with low ISG12 expressing tumors (Figure 8D). This evidence concerns the gene ESR1 and breast carcinoma.